

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Human Genome Sciences, Inc.		12/28/2012	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	GlaxoSmithKline Intellectual Property Limited		
Street Address:	980 Great West Road		
City:	Brentford, Middlesex		
State/Country:	UNITED KINGDOM		
Postal Code:	TW8 9GS		
Entity Type:	CORPORATION: UNITED KINGDOM		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	3329040	ODELVIE	
CORRESPONDENCE DATA			
Fax Number:	7046259190		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	919 483 2723		
Email:	trademarks@gsk.com		
Correspondent Name:	Christopher M. Hanes		
Address Line 1:	Five Moore Drive		
Address Line 2:	LGTM, C.3157.3D		
Address Line 4:	Research Triangle Pa, NORTH CAROLINA 27709		
ATTORNEY DOCKET NUMBER:	ROA/PRJ/7055831/094/PDJ		
DOMESTIC REPRESENTATIVE			
Name:	Christopher M. Hanes		
Address Line 1:	Five Moore Drive		

CH \$40.00 3329040

Address Line 2: LGTM, C.3157.3D
Address Line 4: ResearchTrianglePark, NORTH CAROLINA 27709

NAME OF SUBMITTER:	Christopher M. Hanes
Signature:	/Christopher M. Hanes/
Date:	03/25/2013

Total Attachments: 38

source=HGS_GSK IP Limited_agreement of sale document#page1.tif
source=HGS_GSK IP Limited_agreement of sale document#page2.tif
source=HGS_GSK IP Limited_agreement of sale document#page3.tif
source=HGS_GSK IP Limited_agreement of sale document#page4.tif
source=HGS_GSK IP Limited_agreement of sale document#page5.tif
source=HGS_GSK IP Limited_agreement of sale document#page6.tif
source=HGS_GSK IP Limited_agreement of sale document#page7.tif
source=HGS_GSK IP Limited_agreement of sale document#page8.tif
source=HGS_GSK IP Limited_agreement of sale document#page9.tif
source=HGS_GSK IP Limited_agreement of sale document#page10.tif
source=HGS_GSK IP Limited_agreement of sale document#page11.tif
source=HGS_GSK IP Limited_agreement of sale document#page12.tif
source=HGS_GSK IP Limited_agreement of sale document#page13.tif
source=HGS_GSK IP Limited_agreement of sale document#page14.tif
source=HGS_GSK IP Limited_agreement of sale document#page15.tif
source=HGS_GSK IP Limited_agreement of sale document#page16.tif
source=HGS_GSK IP Limited_agreement of sale document#page17.tif
source=HGS_GSK IP Limited_agreement of sale document#page18.tif
source=HGS_GSK IP Limited_agreement of sale document#page19.tif
source=HGS_GSK IP Limited_agreement of sale document#page20.tif
source=HGS_GSK IP Limited_agreement of sale document#page21.tif
source=HGS_GSK IP Limited_agreement of sale document#page22.tif
source=HGS_GSK IP Limited_agreement of sale document#page23.tif
source=HGS_GSK IP Limited_agreement of sale document#page24.tif
source=HGS_GSK IP Limited_agreement of sale document#page25.tif
source=HGS_GSK IP Limited_agreement of sale document#page26.tif
source=HGS_GSK IP Limited_agreement of sale document#page27.tif
source=HGS_GSK IP Limited_agreement of sale document#page28.tif
source=HGS_GSK IP Limited_agreement of sale document#page29.tif
source=HGS_GSK IP Limited_agreement of sale document#page30.tif
source=HGS_GSK IP Limited_agreement of sale document#page31.tif
source=HGS_GSK IP Limited_agreement of sale document#page32.tif
source=HGS_GSK IP Limited_agreement of sale document#page33.tif
source=HGS_GSK IP Limited_agreement of sale document#page34.tif
source=HGS_GSK IP Limited_agreement of sale document#page35.tif
source=HGS_GSK IP Limited_agreement of sale document#page36.tif
source=HGS_GSK IP Limited_agreement of sale document#page37.tif
source=HGS_GSK IP Limited_agreement of sale document#page38.tif

DATED 28 Dec 2012

HUMAN GENOME SCIENCES, INC

and

GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED

AGREEMENT OF SALE

514204275

TRADEMARK
REEL: 004989 FRAME: 0389

THIS AGREEMENT is made on 2012

BETWEEN:

HUMAN GENOME SCIENCES, INC of 2711 Centreville Road, Suite 400, Wilmington, Delaware 19808, United States (registered in Delaware number 2302223) (the "Seller");

AND

GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED of 980 Great West Road, Brentford TW8 9GS (registered in England number 08283186) (the "Purchaser").

WHEREAS:

- (A) The Seller has agreed to transfer its rights in and rights to use the Entrepreneurial Rights (as defined below) relating to the Assets (as defined below) to the Purchaser; and
- (B) In order to effect the transfer described in Recital (A) above the Seller has agreed to sell and the Purchaser has agreed to purchase the Entrepreneurial Rights relating to the Assets on the terms and subject to the conditions set out in this Agreement and the Seller has agreed to assign its rights under the Transferring Contracts (as defined below) to the Purchaser and the Purchaser has agreed to assume and perform all of the Seller's obligations under the Transferring Contracts on the terms set out in this Agreement.

THIS AGREEMENT PROVIDES as follows:

1. DEFINITIONS

1.1 In this Agreement and schedules:

- "Agreed Form Assignments"** means the assignments of registered intellectual property rights in a form agreed by the Purchaser and Seller;
- "Affiliate"** means any corporation or other business entity controlled by, controlling, or under common control with, the Seller or Purchaser ("control" as used herein meaning the ownership, directly or indirectly, of fifty per cent. (50%) or more of the voting stock or a fifty per cent. (50%) or greater interest in the income of such corporation or other business entity or, in the absence of such ownership, control of the management of such corporation or other business entity);
- "Assets"** means (i) the pharmaceutical product Benlysta and any other pharmaceutical product with the same active pharmaceutical ingredient ("API"), belimumab, and all formulations and all combination products in which the

API is an active ingredient; (ii) the pharmaceutical product Albiglutide and any other pharmaceutical product with this same API, and all formulations and all combination products in which this API is an active ingredient; and (iii) the pharmaceutical product Darapladib and any other pharmaceutical product with this same API, and all formulations and all combination products in which this API is an active ingredient

"Entrepreneurial Rights"

means (i) any rights in designs, copyrights, database rights (whether or not any of these is registered and including applications and rights to apply for registration of any such thing) and all rights or forms of protection of a similar nature or having equivalent or similar effect to any of these which may subsist anywhere in the world; (ii) the Patents and rights in related materials; (iii) the Trade Marks; and (iv) information (whether or not reduced to writing or otherwise recorded on any media) of a confidential nature, including (without limitation) trade secrets, know-how, formulae, processes and methods, designs, research, development, manufacturing, testing and performance data, inventions and improvements to inventions, data relating to clinical trials and regulatory issues (including files relating to regulatory approval of the Products) and to marketing and distribution and any chemical or biological materials;

"Effective Date"

means 31 December 2012;

"Excluded Assets"

means

any right of the Seller to receive any sum from any member of the GSK Group which arises as a result of the Transfer Pricing Review, and the amount of which has been determined on or before 30 June 2013, other than any right of the Seller to receive any sum which arises due to adjustments made to trading prices, sales and/or profits under the Transfer Pricing Review as a result of:

(i) circumstances outside the ordinary course of business, including any such adjustments made as a result of any action, cause of action, demand, claim, suit or proceeding (including any appeal) asserted, anticipated, brought or made against the Seller and in any way connected with the manufacture, use, research, testing, design, marketing, advertising, sale, distribution and/or consumption of the Products; or

(ii) the revaluation of any inventory or stock on or after 1 January 2013;

"GSK Group"	means GlaxoSmithKline plc and its Affiliates;
"GSKTPCE"	means the GlaxoSmithKline Transfer Pricing Centre of Excellence;
"Information"	has the meaning given to it in Clause 9;
"Patents"	means the patents and patent applications listed in Schedule A to this Agreement, and any continuation applications, divisional applications or continuation-in-part applications relating to any of the foregoing, any national or international patent applications claiming priority from any of the foregoing, any patents granted or issued in respect of any of the foregoing, any re-issues, renewals or re-examinations of any of the foregoing and any extensions of the exclusivity granted in connection with any of the foregoing anywhere in the world;
"Products"	means any products sold under the Trade Marks or in relation to which the Trade Marks are used;
"Tax"	includes (without limitation) all taxes, levies, duties, imposts, charges and withholdings of any nature whatsoever, whether of the United Kingdom or elsewhere, together with all penalties, charges and interest relating to any of them or to any failure to file any return required for the purposes of any of them;
"Third Party"	means any person or entity other than the Seller, the Purchaser and their respective Affiliates;
"Third Party Consent"	means all consents, approvals, authorisations or waivers required from Third Parties for assignment of the Entrepreneurial Rights relating to the Assets to the Purchaser;
"Trade Marks"	means the trade marks and trade mark applications listed in Schedule B to this Agreement, together with all goodwill of the business in relation to which such Trade Marks are used (but no other or greater goodwill) anywhere in the world;
"Transferring Contracts"	means the contracts under which the Entrepreneurial Rights relating to, consisting of or subsisting in the Assets is licensed to or by, co-owned by and/or otherwise exploited by the Licensor;

"Transfer Pricing Review" means the GSK Group wide review of trading prices, sales and profits for 2012, to be carried out during 2013; and

"VAT" means:

- (a) within the European Union, any Tax imposed by any Member State in conformity with the Directive of the Council of the European Union on the common system of value added tax (2006/112/EC); and
- (b) outside the European Union, any Tax corresponding to, or substantially similar to, the common system of value added tax referred to in paragraph (a) of this definition.

1.2 In this Agreement, unless otherwise specified:

- (A) references to clauses and schedules are to clauses of, and schedules to, this Agreement;
- (B) use of any gender includes the other genders;
- (C) references to a "company" shall be construed so as to include any corporation or other body corporate, wherever and however incorporated or established;
- (D) references to a "person" shall be construed so as to include any individual, firm, company, corporation, body corporate, government, state or agency of a state, local or municipal authority or government body or any joint venture, association or partnership (whether or not having separate legal personality); and
- (E) a reference to any statute or statutory provision shall be construed as a reference to the same as it may have been, or may from time to time be, amended, modified or re enacted and shall include any subordinate legislation made from time to time under that statute or statutory provision.

1.3 In this Agreement, unless otherwise specified:

- (A) all headings and titles are inserted for convenience only and are to be ignored in the interpretation of this Agreement; and
- (B) the schedules form part of this Agreement and shall have the same force and effect as if expressly set out in the body of this Agreement, and any reference to this Agreement shall include the schedules.

2. ASSIGNMENT OF THE ENTREPRENEURIAL RIGHTS

2.1 With effect from the Effective Date:

(A) the Seller hereby assigns to the Purchaser all of the Seller's rights, title, interest and benefit in and to the Entrepreneurial Rights in or relating to the Assets including all rights, privileges and advantages thereto including, without limitation, the right to bring proceedings and recover damages and obtain all other remedies in respect of previous infringements and previous acts to hold unto the Purchaser absolutely and, where applicable, for the full term of the Entrepreneurial Rights relating to the Assets and to the intent that the Purchaser shall:

- (i) be absolutely entitled to any patent granted on any of the patent applications for the full term of such patents; and
- (ii) have the right to apply for, prosecute and obtain patents or like protection throughout the world for any invention embodied in any of such applications, including the right to claim priority from such applications,

but excluding the Excluded Assets;

(B) the Seller agrees to assign all its rights, title, interest and benefit in and to the Transferring Contracts to the Purchaser, but excluding the Excluded Assets; and

(C) the Purchaser shall assume and agrees to perform, all of the Seller's obligations under the Transferring Contracts on the terms set out in this Agreement.

2.2 Subject to Clause 2.3, Clause 2.1 shall operate as an assignment of such of the Entrepreneurial Rights relating to the Assets as is not the subject of a registration or an application for registration with effect from the Effective Date. Any Entrepreneurial Rights relating to the Assets which is registered or which is the subject of an application for registration shall be assigned to the Purchaser pursuant to the Agreed Form Assignments. In the event of any conflict between this Agreement and the Agreed Form Assignments, this Agreement will prevail.

2.3 Subject to Clause 7.3 and without limitation to Clause 7.2, the sale and purchase of the Entrepreneurial Rights relating to the Assets shall be subject to any encumbrance, lien, charge (whether fixed or floating), mortgage, pledge, other security interest and all other rights exercisable by or claims by a third party existing over such Entrepreneurial Rights relating to the Assets at the Effective Date.

2.4 This Agreement shall not constitute an assignment or attempted assignment of any:

- (A) Entrepreneurial Rights relating to the Assets if such assignment or attempted assignment would constitute a breach of the terms of any other agreement or document or would require a Third Party Consent; or
- (B) Transferring Contract if such assignment or attempted assignment would be a breach of such Transferring Contract.

2.5 Where a Third Party Consent is required to the assignment of the Entrepreneurial Rights relating to the Assets or Transferring Contracts:

- (A) the Seller shall be responsible (both before and after the Effective Date at the Purchaser's expense) for obtaining and shall use all reasonable endeavours to obtain any such Third Party Consent; and
- (B) until such Third Party Consent is obtained the Seller shall account to the Purchaser for any moneys received in connection with such Entrepreneurial Rights relating to the Assets.

2.6 Upon whichever is the later of Effective Date and any such Third Party Consent being obtained:

- (A) in respect of a Third Party Consent relating to Entrepreneurial Rights relating to the Assets, this Agreement shall operate as an assignment of all Seller's rights, title, interest and benefit in and to such of the Entrepreneurial Rights relating to the Assets as is not the subject of a registration or an application for registration with effect from Effective Date on the terms set out in Clause 2.1(A)(i). Any such Entrepreneurial Right relating to the Assets which is registered or which is the subject of an application for registration shall be assigned to the Purchaser pursuant to the Agreed Form Assignments. In the event of any conflict between this Agreement and the Agreed Form Assignments, this Agreement will prevail; and
- (B) in respect of a Third Party Consent relating to a Transferring Contract this Agreement shall constitute an assignment of all Seller's rights, title, interest and benefit in and to the Transferring Contract to the Seller, but excluding the Excluding Assets.

2.7 The Seller shall, on the Effective Date, deliver to the Purchaser all documents or other records relating to the Entrepreneurial Rights relating to the Assets within the Seller's possession or control (including such documents or records held by the Seller's patent agents and advisers and trade mark agents and advisers).

3. OPTION

3.1 The Purchaser shall have the right at any time to request an assignment by the Seller to the Purchaser of all or any other Entrepreneurial Rights owned or licensed to the Seller which are not transferred to the Purchaser pursuant to Clause 2.1 with the exception of any Entrepreneurial Rights in or relating to the pharmaceutical product Raxibacumab and any other pharmaceutical product with this same API, and all formulations and all combination products in which this API is an active ingredient (the "**Retained Entrepreneurial Rights**"). The Seller shall, as soon as practicable, and in any event not later than 2 (two) months from the date of that request assign, transfer or convey for no consideration the Retained Entrepreneurial Rights to the Purchaser or, at the request of the Purchaser, an Affiliate of the Purchaser nominated by the Purchaser.

3.2 The Seller shall not enter into any agreement, arrangement or licence in relation to any Retained Entrepreneurial Rights with an Affiliate or a Third Party without the consent of the Purchaser.

4. CONSIDERATION

The consideration for the sale of the Entrepreneurial Rights relating to the Assets and the assignment of the Transferring Contracts and the option granted pursuant to Clause 3 under this Agreement shall be the payment of \$1,936,595,717 (US Dollars) (exclusive of VAT) from the Purchaser to the Seller. The payment shall be effectuated at such time and manner as the Parties agree.

5. FURTHER ASSURANCE

- 5.1 The Seller shall from time to time and at the cost of, the Purchaser, do or procure the carrying out of all such acts and/or execute or procure the execution of all such documents as the Purchaser may request:
- (A) to give full effect to this Agreement and secure to the Purchaser or any successor in title thereof the full benefit of the rights assigned to the Purchaser hereunder; and
 - (B) to assist in obtaining other patents or similar protection for the inventions claimed in any of the Patents and any improvements of such Patents in any part of the world.
- 5.2 The Seller shall provide the Purchaser with such assistance as the Purchaser may from time to time require for the purpose of defending or enforcing any of the Entrepreneurial Rights relating to the Assets including but not limited to becoming a party or lending its name to proceedings, provided that the Purchaser indemnifies the Seller for all reasonable costs and damages incurred by it as a result.

6. WARRANTIES

- 6.1 The Seller represents and warrants to the Purchaser that:
- (A) it is a company duly incorporated and validly existing under the laws of Delaware;
 - (B) it has the requisite capacity, power and authority to enter into and perform this Agreement;
 - (C) this Agreement constitutes valid and binding obligations of the Seller in accordance with their terms;
 - (D) the execution and delivery of this Agreement, and the performance by the Seller of its obligations under this Agreement, will not:
 - (i) result in a breach of any order, judgment or decree of any court, governmental agency or regulatory body by which it is bound; or
 - (ii) require the consent of its shareholders or of any other person (other than such consent as has been obtained prior to or will be obtained on the date of this Agreement);

- (E) it is the sole legal and beneficial owner of the Entrepreneurial Rights in the Assets;
- (F) none of the Entrepreneurial Rights in the Assets is the subject of any litigation, opposition or mediation or administrative, criminal or other proceedings;

6.2 The Purchaser represents and warrants to the Seller that:

- (A) it is a company duly incorporated and validly existing under the laws of England;
- (B) it has the requisite capacity, power and authority to enter into and perform this Agreement;
- (C) this Agreement constitutes valid and binding obligations of the Purchaser in accordance with their terms; and
- (D) the execution and delivery of this Agreement, and the performance by the Purchaser of its obligations under this Agreement, will not:
 - (i) result in a breach of any order, judgment or decree of any court, governmental agency or regulatory body by which it is bound; or
 - (ii) require the consent of its shareholders or of any other person (other than such consent as has been obtained prior to or will be obtained on the date of this Agreement).

7. ASSUMED OBLIGATIONS

7.1 Except as otherwise provided in this Agreement, the Purchaser undertakes to the Seller that, with effect from the Effective Date, it will properly perform, assume and pay and discharge when due, and indemnify the Seller on an after-tax basis against, all Assumed Obligations.

7.2 In this Agreement, "**Assumed Obligations**" means all obligations and liabilities of the Seller (whether arising before, at or after the Effective Date):

- (A) under the Transferring Contracts;
- (B) arising in connection with the Entrepreneurial Rights relating to the Assets; and/or
- (C) arising in connection with Seller's exploitation of the Entrepreneurial Rights relating to the Assets, including obligations and liabilities arising in connection with Seller's research and development, manufacture, formulation, use and sale of Products,

but excluding the Excluded Obligations and obligations and liabilities of the Seller which arise through fraud, gross negligence or wilful default.

- 7.3 In this Agreement, "**Excluded Obligations**" means any obligations or liabilities of the Seller:
- (A) which arise in favour of GlaxoSmithKline plc, or any of its Affiliates from time to time, as a result of the Transfer Pricing Review, and the amount of which has been determined by the GSKTPCE on or before 30 June 2013, other than any obligations or liabilities arising due to adjustments made to trading prices, sales and/or profits under the Transfer Pricing Review as a result of:
 - (i) circumstances outside the ordinary course of business, including any such adjustments made as a result of any action, cause of action, demand, claim, suit or proceeding (including any appeal) asserted, anticipated, brought or made against the Seller and in any way connected with the manufacture, use, research, testing, design, marketing, advertising, sale, distribution and/or consumption of the Products; or
 - (ii) the revaluation of any inventory or stock on or after 1 January 2013; or
 - (B) to pay any royalties or licence fees or any other payments due under the Transferring Contracts or in connection with the Entrepreneurial Rights relating to the Assets relating to the period up to and including the Effective Date.
- 7.4 The Seller shall properly perform, assume and pay and discharge when due, and indemnify the Purchaser on an after-tax basis against, all Excluded Obligations.
- 7.5 If any action, claim or demand is brought or alleged against a party to this Agreement (the "**Relevant Indemnified Party**") in respect of which an indemnity is to be sought from the other party to this Agreement (the "**Relevant Indemnifying Party**") pursuant to this Clause 7, the Relevant Indemnified Party shall forthwith notify the Relevant Indemnifying Party therefore and the Relevant Indemnifying Party shall have the option to assume the defence thereof.
- 8. MISDIRECTED PAYMENTS / WRONG POCKETS**
- 8.1 All moneys or other items belonging to the Purchaser which are received by the Seller on or after the Effective Date in connection with any Transferring Contract or any of the Entrepreneurial Rights relating to the Assets shall be held in trust by the Seller for the Purchaser and shall be promptly paid over to the Purchaser.
- 8.2 All moneys or other items belonging to the Seller which are received by the Purchaser on or after the Effective Date in connection with the Excluded Assets shall be held in trust by the Purchaser for the Seller and shall be promptly paid over to the Seller.
- 9. CONFIDENTIALITY**
- 9.1 The Seller shall treat as confidential all information relating to the Transferring Contracts and the Entrepreneurial Rights relating to the Assets (the "**Information**") assigned to the Purchaser under this Agreement and save to the extent permitted under the terms of any other agreement the Seller shall not make use of any such Information.

9.2 Notwithstanding the other provisions of this Clause 9, the Seller may disclose any such Information:

- (A) to the extent required by law or for the purpose of any judicial proceedings;
- (B) to the extent required by existing contractual obligations;
- (C) to the extent required by any securities exchange, tax authority or other regulatory or governmental body to which the Seller is subject, wherever situated and whether or not the requirement for information has the force of law;
- (D) to the extent required to vest the full benefit of this Agreement in the Seller;
- (E) to its professional advisers, auditors and bankers provided they have a duty to keep such Information confidential;
- (F) to the extent the Information has come into the public domain through no fault of the Seller; or
- (G) to the extent the Purchaser has given consent to the disclosure.

9.3 Any information to be disclosed pursuant to sub-clauses (A), (B) or (C) shall be disclosed only after, to the extent permitted by law, notice to the Purchaser.

9.4 The obligations under this Clause 9 shall survive termination of this Agreement.

10. ASSIGNMENT

The Purchaser may at any time assign all or any part of the benefit of, or its rights or benefits under, this Agreement and any other documents referred to in it (including without limitation the Warranties (together with any causes of action arising in connection with any of them)).

11. CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999

The parties to this Agreement do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is not a party to this Agreement.

12. ENTIRE AGREEMENT

This Agreement and the Agreed Form Assignments sets out the entire agreement and understanding between the parties in connection with the subject matter of this Agreement.

13. COUNTERPARTS

13.1 This Agreement may be executed in any number of counterparts, and by the parties on separate counterparts, but shall not be effective until each party has executed at least one counterpart.

- 13.2 Each counterpart shall constitute an original of this Agreement, but all the counterparts shall together constitute but one and the same instrument.

14. GOVERNING LAW

This Agreement is to be governed by and construed in accordance with English law. Any matter, claim or dispute arising out of or in connection with this Agreement, whether contractual or non-contractual, is to be governed by and determined in accordance with English law.

15. JURISDICTION

- 15.1 The courts of England are to have exclusive jurisdiction to settle any dispute, whether contractual or non-contractual, arising out of or in connection with this Agreement. Any proceeding, suit or action arising out of or in connection with this Agreement or the negotiation, existence, validity or enforceability of this Agreement ("**Proceedings**") shall be brought only in the courts of England.
- 15.2 Each party waives (and agrees not to raise) any objection, on the ground of *forum non conveniens* or on any other ground, to the taking of Proceedings in the courts of England. Each party also agrees that a judgment against it in Proceedings brought in England shall be conclusive and binding upon it and may be enforced in any other jurisdictions.
- 15.3 Each party irrevocably submits and agrees to submit to the jurisdiction of the courts of England.

IN WITNESS of which this document has been executed on the date which appears on page 1 above.

Schedule A

PATENTS

Docket	Country/ Region	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Issue Date	Status
PF343AT	AT	96939612.6	25/10/1996	0939804	08/09/1999	E302272	17/08/2005	Granted
PF343AU	AU	76745/96	25/10/1996	731553	05/04/2001	731553	19/07/2001	Granted
PF343AU2	AU	30028/00	22/02/2000	777536	21/10/2004	777536	16/06/2005	Granted
PF343AU2D1	AU	2005200237	20/01/2005			2005200237	13/03/2008	Granted
PF343AUD1	AU	54180/01	07/03/2001	779750		779750	23/06/2005	Granted
PF343BE	BE	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343BRD1	BR	PI9612958-1	21/11/2005					Pending
PF343CA	CA	2,266,439	25/10/1996			2,266,439	16/06/2009	Granted
PF343CH	CH	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343CN2	CN	00806541.1	22/02/2000	CN1451044	22/10/2003	ZL00806541.1	26/01/2009	Granted
PF343CN2D1	CN	200710153785.6	25/09/2007	CN101210244A	02/07/2008			Published
PF343CND2	CN	200710154399.9	25/10/1996	CN 101157924A	09/04/2008			Published
PF343DE	DE	96939612.6	25/10/1996	0939804	08/09/1999	69635088.2	17/08/2005	Granted
PF343DK	DK	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343EP	EP	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343EP2D1	EP	07012741.0	22/02/2000	1860190	28/11/2007			Published
PF343EPD2	EP	10156941.6	25/10/1996	2230307	22/09/2010			Published
PF343ES	ES	96939612.6	25/10/1996	0939804	08/09/1999	2248823 T3	17/08/2005	Granted
PF343FI	FI	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343FR	FR	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343GB	GB	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Opposed
PF343GR	GR	20050403506	25/10/1996	0939804	08/09/1999	3055514	17/08/2005	Granted
PF343HK2D1	HK	08105027.8	22/02/2000	1110628A	18/07/2008			Published
PF343HK2D2	HK	08114115.3	25/09/2007	CN101210244A	02/07/2008			Published
PF343HKD2	HK	08106030.1	25/10/1996	111195A	01/08/2008			Published
PF343HKD3	HK	11102301.7	25/10/1996	1148308A	02/09/2011			Published
PF343IE	IE	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343IT	IT	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343JPD4	JP	2011-242255	04/11/2011	2012-044999	08/03/2012			Published
PF343KR2	KR	2001-7010786	22/02/2000			716444	03/05/2007	Granted
PF343LU	LU	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted

PF343MC	MC	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343MX	MX	1999/002973	25/10/1996	233604	31/10/2007	233604	10/01/2006	Granted
PF343MX2	MX	PA/a/2001/008565	22/02/2000			290419	22/09/2011	Granted
PF343MX2D1	MX	MX/a/2008/010059	22/02/2000					Pending
PF343NL	NL	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343NZ	NZ	334309	25/10/1996	1454	25/08/2000	334309	07/12/2000	Granted
PF343NZ2	NZ	513290	22/02/2000			513290	09/09/2004	Granted
PF343NZ2D1	NZ	529555	22/02/2000	529555	30/09/2005	529555	12/01/2006	Granted
PF343NZD2	NZ	505580	05/07/2000			505580	07/04/2005	Granted
PF343NZD3	NZ	514848	25/10/1996	514848	28/03/2003	514848	07/07/2003	Granted
PF343P1	US	09/005,874	12/01/1998			6,689,579	10/02/2004	Granted
PF343P2	US	09/255,794	23/02/1999			6,716,576	06/04/2004	Granted
PF343P3	US	09/507,968	22/02/2000			6,812,327	02/11/2004	Granted
PF343P3C1	US	09/589,287	08/06/2000			6,403,770	11/06/2002	Granted
PF343P3C10	US	12/393,693	26/02/2009	20090169565	02/07/2009			Published
PF343P3C13	US	12/870,548	27/08/2010	2012/0039890	16/02/2012	8,231,873		Granted
PF343P3C2	US	09/588,947	08/06/2000			6,562,579	13/05/2003	Granted
PF343P3C3	US	09/589,286	08/06/2000			6,635,482	21/10/2003	Granted
PF343P3C4	US	09/589,285	08/06/2000			6,881,401	19/04/2005	Granted
PF343P3C5	US	09/589,288	08/06/2000			8071092	06/12/2011	Granted
PF343P3C9	US	12/170,333	09/07/2008	20090068201	12/03/2009	8,173,122		Granted
PF343P6	US	11/054,539	10/02/2005	20050186637	25/08/2005	8,212,004		Granted
PF343P6C2	US	12/952,091	22/11/2010	2012/0045432	23/02/2012			Allowed
PF343P6C3	US	12/965,535	10/12/2010	2011/0165160	07/07/2011			Published
PF343PT	PT	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF343SE	SE	96939612.6	25/10/1996	0939804	08/09/1999	0939804	17/08/2005	Granted
PF523AU	AU	2001268427	15/06/2001	2001268427	29/03/2007	2001268427	19/07/2007	Granted
PF523AUD1	AU	2007202950	15/06/2001	2007202950	02/08/2007	2007202950	30/06/2011	Granted
PF523AUD2	AU	2009200977	15/06/2001	2009200977	02/04/2009			Published
PF523CA	CA	2,407,910	15/06/2001	WO 2002/002641	10/01/2002			Published
PF523CAD1	CA	2,585,012	27/04/2007	WO 2002/002641	10/01/2002			Published
PF523CN	CN	01811296.X	15/06/2001	1492878A	28/04/2004	ZL01811296.X	11/10/2006	Granted

PF523DE	DE	60143798.5	15/06/2011	1294769	26/03/2003	1294769	05/01/2011	Granted
PF523EP	EP	01946365.2	15/06/2001	1294769	26/03/2003	1294769	05/01/2011	Opposed
PF523EPD1	EP	10185178	01/10/2010	2275449	19/01/2011			Published
PF523EPD2	EP	10185182.2	01/10/2010	2281842	09/02/2011			Published
PF523EPD3	EP	10185185.5	01/10/2010	2281843	09/02/2011			Published
PF523HK	HK	03103931.3	15/06/2001	1051697A	15/08/2003	1051697A	09/09/2011	Granted
PF523HKD1	HK	11107473.8	01/10/2010	2275449	19/01/2011			Published
PF523HKD2	HK	11107919	01/10/2010	2281842	09/02/2011			Published
PF523HKD3	HK	11108269.4	01/10/2010	2281843	09/02/2011			Published
PF523JP	JP	2002-507892	15/06/2001	04-509615	02/04/2004	4902087	13/01/2012	Granted
PF523JPD1	JP	2008-257439	02/10/2008	95346/2009	07/05/2009	4902618	13/01/2012	Granted
PF523KR	KR	10-2002-7017188	15/06/2001	WO 2002/002641	10/01/2002			Published
PF523KRD2	KR	10-2010-7026974	30/11/2010					Pending
PF523MX	MX	PA/A/2002/012434	15/06/2001			258900	18/07/2008	Granted
PF523MXD1	MX	06/012832	15/06/2001	WO 2002/002641	10/01/2002			Published
PF523NZ	NZ	522700	15/06/2001		24/02/2006	522700	08/06/2006	Granted
PF523P1	US	09/880,748	15/06/2001	03/0059937	27/03/2003	7,138,501	21/11/2006	Granted
PF523P1D1	US	11/266,444	04/11/2005	06/0062789	23/03/2006	7,605,236	20/10/2009	Granted
PF523P1D2	US	12/552,915	02/09/2009	20100003259	07/01/2010	8,101,181	24/01/2012	Granted
PF523P1D3	US	13/356,314	23/01/2012					Pending
PF523P2	US	10/293,418	14/11/2002	03/0223996	04/12/2003	7,220,840	22/05/2007	Granted
PF523P3	US	11/054,515	10/02/2005	20050255532	17/11/2005	7,879,328	01/02/2011	Granted
PF523P3C2	US	12/914,741	28/10/2010	20110117093	19/05/2011			Published
PF523P3C3	US	13/209,197	12/08/2011	20110293610	01/12/2011			Published
PF524P1	US	09/961,376	25/09/2001	02/0106736	08/08/2002	6969519	29/11/2005	Granted
PF524P1D1	US	11/221,849	09/09/2005	06/0003380	05/01/2006	7498027	03/03/2009	Granted
PF524P1D2	US	12/336,051	16/12/2008	2009-0142353	04/06/2009			Published
PF526C1N	US	10/786,176	26/02/2004			7,371,388	13/05/2008	Granted
PF526C1D1C1	US	12/892,534	28/09/2010	2011/0020380	27/01/2011			Published
PF528	US	09/932,322	17/08/2001	03/0194743	16/10/2003	7118872	10/10/2006	Granted

PF528AU	AU	2001285066	17/08/2001	2001285066	29/06/2006	2001285066	12/10/2006	Granted
PF528CA	CA	2418006	17/08/2001					Pending
PF528EPD1	EP	6005641.3	17/08/2001	1674477	28/06/2006	1674477	09/12/2009	Granted
PF528EPD2	EP	9178022.1	07/12/2009	2184291	12/05/2010			Published
PF528EPD3	EP	10011242.4	28/09/2010	2267020	29/12/2010			Published
PF528HKD2	HK	10106220.7	23/06/2010	1139424A	17/09/2010			Published
PF528HKD3	HK	11100330.6	13/01/2011	1145261A	08/04/2011			Published
PF528JP	JP	2002-521507	17/08/2001	2004-532604	28/10/2004			Published
PF528JPD1	JP	2012-045428	01/03/2012					Pending
PF529C2	US	12/701,301	05/02/2010	2010/0144058	10/06/2010	8062906	22/11/2011	Granted
PF529C3	US	13/239,604	22/09/2011	20120022006	26/01/2012			Published
PF529WO	WO	US01/25850	17/08/2001	WO20002016411	28/02/2002			Published
PF562N	US	10/229,352	28/08/2002			7,112,410	26/09/2006	Granted
PF562D1C1D1	US	13/295,221	14/11/2011	2012/0058119	08/03/2012			Published
PF620AU	AU	2006344395	05/10/2006					Pending
PF620BR	BR	PI06172679	05/10/2006					Pending
PF620CA	CA	2,626,082	05/10/2006					Pending
PF620CN	CN	200680047110.7	05/10/2006	CN101512007A	19/08/2009			Published
PF620CO	CO	08048349	05/10/2006	556	31/08/2009			Published
PF620CR	CR	9968	05/10/2006					Pending
PF620DZ	DZ	080241	05/10/2006			5806	23/08/2011	Granted
PF620EA	EA	200801071	05/10/2006			15860	30/12/2011	Granted
PF620EG	EG	602/2008	05/10/2006					Pending
PF620EP	EP	06851283.9	05/10/2006	1933873	25/06/2008			Published
PF620HK	HK	08109531.9	05/10/2006	1114020A	24/10/2008			Published
PF620ID	ID	WO0200801212	05/10/2006	048.2767 A	03/07/2008			Published
PF620IL	IL	190733	05/10/2006					Pending
PF620ILD1	IL	217632	19/01/2012					Pending
PF620IN	IN	3565/DELINP/2008	05/10/2006					Pending
PF620JP	JP	2008-535568	05/10/2006	2009-521398	04/06/2009			Published

PF620KR	KR	10-2008-7011124	05/10/2006														Pending
PF620MA	MA	30898	05/10/2006														Pending
PF620MX	MX	MX/A/2008/004815	05/10/2006								02/09/2008						Published
PF620MXD1	MX	MX/A/2011/003586	04/04/2011														Pending
PF620NG	NG	NG/C/2008/205	05/10/2006												RP:NG/C/2008/205	19/11/2009	Granted
PF620NO	NO	2008-1842	05/10/2006														Pending
PF620NZ	NZ	568204	05/10/2006	568204							27/01/2012						Allowed
PF620NZD1	NZ	597082	13/12/2011														Pending
PF620P1	US	12/135,025	06/06/2008	20090148462							11/06/2009						Published
PF620PH	PH	1-2008-500887	05/10/2006														Pending
PF620SGD1	SG	201007657-8	13/10/2010	166177							29/11/2010						Published
PF620TT	TT	TT/A/2008/0082	05/10/2006														Pending
PF620UA	UA	200806028	05/10/2006														Pending
PF620USP0	US	12/295,572	30/09/2008	20100261207							14/10/2010	8,211,649					Granted
PF620ZA	ZA	2008/03855	05/10/2006														Pending
PF621	US	12/705,551	12/02/2010	2011/0014190							20/01/2011						Published
PF621EP	EP	10741848.5	12/09/2011	2396035							21/12/2011						Published
PF624	US	13/163,593	17/06/2011	2011/0311548							22/12/2011						Published

Docket	Country/R egion	Application Number	Filing Date	Publication Number	Date	Patent Number	Issue Date	Status	Patent/ Publication Link
PF539D3	US	10/237,624	10/09/2002	03/0082747	01/05/2003	7,056,701	06/06/2006	Granted	Link
PF539D3D1	US	11/330,353	12/01/2006	06/0105429	18/05/2006	7,410,779	12/08/2008	Granted	Link
PF539D3D1D1	US	11/927,628	29/10/2007	2009/0176276	09/07/2009	7,833,521	16/11/2010	Granted	Link
PF564	US	10/775,204	02/11/2004	20050186664	08/25/2005	7,141,547	11/28/2006	Granted	Link
PF564C1	US	11/429,373	05/08/2006	20060276396	12/07/2006	7,238,667	07/03/2007	Granted	Link
PF564C1D1	US	11/783,419	04/09/2007	20070259815	11/08/2007			Abandoned	Link
PF564C1D1C1	US	12/836,447	07/14/2010	20110009312	01/13/2011	8,074,539	12/06/2011	Granted	Link
PF564C1D1C2	US	13/078,827	04/01/2011					Pending	
PF564C1D1C3	US	13/078,708	04/01/2011	20120046221	02/23/2012			Allowed	Link
PF564C3	US	11/772,643	07/02/2007	20080146503	06/19/2008	7,799,759	09/21/2010	Granted	Link
PF564CA	CA	2,471,363	12/23/2002					Pending	Link
PF564D1	US	11/429,374	05/08/2006	20080213886	09/04/2008	7,847,079	12/07/2010	Granted	Link
PF564EP	EP	02799966.3	12/23/2002	1463751	10/06/2004			Allowed	Link
PF564JP	JP	2003-560158	12/23/2002					Published	
PF564JPD2	JP	2009-109615	04/28/2009					Pending	
PF564PP	US	60/341,811	12/21/2001					Converted	
PF564PP2	US	60/360,000	02/28/2002					Converted	
PF564PP3	US	60/378,950	05/10/2002					Converted	
PF564PP4	US	60/398,008	07/24/2002					Converted	
PF564PP5	US	60/411,355	09/18/2002					Converted	
PF564PP6	US	60/414,984	10/02/2002					Converted	
PF564PP7	US	60/417,611	10/11/2002					Converted	
PF564PP8	US	60/420,246	10/23/2002					Converted	
PF564PP9	US	60/423,623	11/05/2002					Converted	
PF564WO	WO	US02/40891	12/23/2002	WO03/60071	07/24/2003			Inactive	Link
PF574	US	10/775,180	02/11/2004	20050054570	03/10/2005	7,189,690	03/13/2007	Granted	Link
PF574	WO	US02/40892	12/23/2002	WO03/59934	07/24/2003			Inactive	Link
PF574C1	US	11/393,893	03/31/2006	20060286635	12/21/2006	7,238,660	07/03/2007	Granted	Link
PF574C2	US	11/772,591	07/02/2007	20080293629	11/27/2008	7,977,306	07/12/2011	Granted	Link
PF574C3	US	13/078,804	04/01/2011					Pending	
PF574CA	CA	2,484,556	12/23/2002					Abandoned	Link
PF574EP	EP	02799967.1	12/23/2002	1463752	10/06/2004			Abandoned	Link
PF574PP	US	60/350,358	01/24/2002					Converted	

PF574PP2	US	60/359,370	02/26/2002	20060014254	19/01/2006	7,521,424	21/04/2009	Converted	Link
PF574PP3	US	60/367,500	03/27/2002					Converted	Link
PF574PP4	US	60/402,131	08/09/2002					Converted	
PF574PP5	US	60/402,708	08/13/2002					Converted	
PF605	US	11/175,690	07/07/2005					Granted	
PF605CA	CA	2,513,213	07/12/2005					Pending	
PF605PP	US	60/441,305	01/22/2003					Converted	
PF605PP2	US	PF605PP2	03/11/2003					Converted	
PF605PP3	US	60/467,222	05/02/2003					Converted	
PF605PP4	US	60/472,816	05/23/2003					Converted	
PF605PP5	US	60/476,267	06/06/2003					Converted	
PF605PP6	US	60/505,172	09/24/2003					Converted	
PF605PP7	US	60/506,746	09/30/2003					Converted	
PF605WO	WO	US2004/001369	01/20/2004	WO05/003296	13/01/2005			Inactive	Link
PF612AU	AU	2005211725	02/09/2005			2005211725	02/17/2011	Granted	Link
PF612AUD1	AU	2010227035	10/07/2010					Abandoned	Link
PF612BR	BR	PI05070260	02/09/2005				04/17/2007	Published	Link
PF612CA	CA	2,554,089	02/09/2005					Allowed	
PF612CN	CN	200580012252.5	02/09/2005	CN1980687A	06/13/2007			Published	
PF612CO	CO	06-089.815	02/09/2005	734	12/18/2007			Published	
PF612DZ	DZ	060447	02/09/2005			4676	03/22/2009	Granted	
PF612EG	EG	738/2006	02/09/2005					Published	Link
PF612EP	EP	05722848.8	02/09/2005	1729795	12/13/2006			Published	
PF612HK	HK	07101008.1	02/09/2005	1095087	04/27/2007			Published	
PF612ID	ID	W-00200602194	02/09/2005	048.0490 A	02/14/2008			Published	
PF612IL	IL	176894	02/09/2005					Published	
PF612IN	IN	4362/DELNP/2006	02/09/2005	4362/DELNP/2006	08/10/2007			Published	
PF612JM	JM	18/1/4522	02/09/2005					Pending	
PF612JP	JP	2006-553197	02/09/2005	2007-522806A	08/16/2007			Published	
PF612JPD1	JP	2012-041914	02/28/2012					Pending	
PF612KR	KR	10-2006-7018484	02/09/2005	2007-0016119	02/07/2007			Published	
PF612MA	MA	PV/29305	02/09/2005			28565	05/02/2007	Granted	
PF612MX	MX	PA/a/2006/009072	02/09/2005	PA/a/2006/009072	07/18/2007			Allowed	
PF612MXD1	MX	MX/a/2011/004879	05/06/2011					Allowed	
PF612NG	NG	143/06	02/09/2005					Published	
PF612NO	NO	20064059	02/09/2005					Published	

PF612NZ	NZ	548612	02/09/2005	548612	10/16/2009	548612	03/11/2010	Granted	
PF612NZD1	NZ	580118	09/29/2009					Abandoned	Link
PF612P1	US	11/500,314	08/08/2006	20070048282	03/01/2007			Abandoned	Link
PF612P2	US	11/500,508	08/08/2006	20070027306	02/01/2007	7,569,384	08/04/2009	Granted	Link
PF612P2D1	US	12/534,585	08/03/2009	20100093627	04/15/2010	8,143,026	03/27/2012	Granted	Link
PF612PH	PH	1-2006-501460	02/09/2005					Published	
PF612PP	US	60/542,274	02/09/2004					Converted	
PF612PP2	US	60/549,901	03/05/2004					Converted	
PF612PP3	US	60/556,906	03/29/2004					Converted	
PF612PP4	US	60/636,603	12/17/2004					Converted	
PF612RU	RU	2006132384	02/09/2005			2369404	10/10/2009	Granted	
PF612SG	SG	200604833-4	02/09/2005			124099	08/31/2009	Granted	
PF612TT	TT	TT/A/2006/00141	02/09/2005					Abandoned	
PF612VN	VN	1-2006-01476	02/09/2005					Published	
PF612WO	WO	US2005/004041	02/09/2005	WO05/077042	08/25/2005			Inactive	Link
PF612ZA	ZA	2006/05871	02/09/2005			2006/05871	02/27/2008	Granted	

Schedule B

TRADE MARKS

Country	Mark	Status	Application #	Registration #	WIPO
Albania	OELVIE	Registered	926205	926205	Yes
Algeria	BENLYSTA	Application	112683		No
Algeria	OELVIE	Registered	080214	071411	No
Antigua and Barbuda	OELVIE	Registered	926205	926205	Yes
Argentina	BENLISTA	Registered	2853939	2311934	No
Argentina	BENLYSTA	Registered	2853937	2311936	No
Argentina	BENLYSTIA	Registered	2853938	2311935	No
Argentina	LINBELIN	Registered	2853936	2311937	No
Argentina	OELVIE	Registered	2799114	2268392	No
Armenia	OELVIE	Registered	926205	926205	Yes
Aruba	OELVIE	Registered	IM08022015	27132	No
Australia	ADEPZAR	Registered	898897	898897	No
Australia	BENLISTA	Registered	1236342	1236342	No
Australia	BENLYSTA	Registered	117892	117892	No
Australia	BENLYSTIA	Registered	1236346	1236346	No
Australia	BLYS	Registered	819890	819890	No
Australia	LERSENA	Registered	934512	934512	Yes
Australia	LINBELAR	Registered	1236343	1236343	No
Australia	LINBELIN	Registered	1236344	1236344	No
Australia	OELVIE	Registered	926205	926205	Yes
Australia	VARSIMLA	Registered	1178900	1178900	No
Australia	VELARBA	Registered	1178903	1178903	No
Azerbaijan	BENLYSTA	Application	20111827		No
Azerbaijan	OELVIE	Registered	926205	926205	Yes

Bahamas	OELVIE	Application	32148		No
Bahrain	BENLYSTA	Application	90434		No
Bahrain	OELVIE	Registered	926205	926205	Yes
Bangladesh	OELVIE	Registered	111625	111625	No
Barbados	OELVIE	Application	8124296		No
Belarus	BENLYSTA	Application	1097721	1097721	Yes
Belarus	OELVIE	Registered	926205	926205	Yes
Bermuda	OELVIE	Registered	47717	47717	No
BES Islands (Bonaire, Sint Eustatius and Saba)	OELVIE	Registered	926205	926205	Yes
Bhutan	OELVIE	Registered	926205	926205	Yes
Bolivia	OELVIE	Registered	SM03872008	116207C	No
Bosnia and Herzegovina	BENLYSTA	Application	BAZ1115839A		No
Bosnia and Herzegovina	OELVIE	Registered	BAZ0812322A	BAZ0812322	No
Botswana	OELVIE	Registered	926205	926205	Yes
Botswana	OELVIE	Registered	BWM0800385	BWM0800385	No
Brazil	BENLISTA	Registered	829972064	829972064	No
Brazil	BENLYSTA	Registered	829972080	829972080	No
Brazil	BENLYSTIA	Registered	829972110	829972110	No
Brazil	LINBELIN	Registered	830066756	830066756	No
Brazil	OELVIE	Registered	829626328	829626328	No
Brunei	OELVIE	Registered	39417	39417	No
Bulgaria	BENLYSTA/BENLISTA in russian cyrillic	Registered	114673	80496	No

Bulgaria	BENLYSTIA in cyrillic	Registered	114674	80497	No
Bulgaria	ODELVIE in bulgarian cyrillic	Registered	107063	74380	No
Cambodia	ODELVIE	Registered	3004308	KH3311410	No
Canada	BENLYSTA	Application	1349447		No
Canada	BUTTERFLY device	Application	1537402		No
Canada	LE PROGRAMME MONARQUE	Application	1537403		No
Canada	LERSENA	Application	1357210		No
Canada	LYMPHOSTAT-B	Registered	1126886	TMA621843	No
Canada	MONARCH PROGRAM	Application	1537404		No
Canada	THE US IN LUPUS	Application	1526954		No
Canada	VARSIMLA	Application	1349450		No
Canada	VELARBA	Application	1349451		No
Chile	BENLISTA	Registered	843923	856709	No
Chile	BENLYSTA	Registered	843926	877913	No
Chile	BENLYSTIA	Registered	843924	856708	No
Chile	LINBELIN	Registered	843925	856707	No
Chile	ODELVIE	Registered	806374	829642	No
China (Peoples Republic)	BENLISTA	Registered	6993339	6993339	No
China (Peoples Republic)	BENLISTA in chinese (Bei Li Teng)	Registered	9118139	9118139	No
China (Peoples Republic)	BENLYSTA	Registered	6993342	6993342	No
China (Peoples Republic)	BENLYSTA in chinese (Ban Li Da)	Registered	9118140	9118140	No
China (Peoples Republic)	BENLYSTIA	Registered	6993340	6993340	No

China (Peoples Republic)	BENLYSTIA in chinese (Bi Li Da)	Registered	9118137	9118137	No
China (Peoples Republic)	BENLYSTIA in chinese (Bi Li Te)	Registered	9118138	9118138	No
China (Peoples Republic)	LINBELIN	Registered	6993341	6993341	No
China (Peoples Republic)	ODELVIE	Registered	926205	926205	Yes
Colombia	BENLISTA	Registered	08096171	379630	No
Colombia	BENLYSTA	Registered	08096173	379631	No
Colombia	BENLYSTIA	Registered	08096176	379632	No
Colombia	LINBELIN	Registered	08096170	380072	No
Colombia	ODELVIE	Registered	08009850	369690	No
Congo (Democratic Republic)	ODELVIE	Application			No
Costa Rica	BENLYSTA	Application	20110012044		No
Costa Rica	ODELVIE	Registered	20081119	181905	No
Croatia	BENLYSTA	Application	Z20111549A		No
Croatia	ODELVIE	Registered	926205	926205	Yes
Cuba	ODELVIE	Registered	926205	926205	Yes
Curacao	ODELVIE	Registered	926205	926205	Yes
Dominican Republic	ODELVIE	Registered	200835560	171230	No
Ecuador	BENLYSTA	Application	201115058		No
Ecuador	ODELVIE	Application	195017		No
Egypt	BENLYSTA	Application	265086		No
Egypt	ODELVIE	Application	214098		No
El Salvador	BENLYSTA	Registered	20110160315	33 Book 191	No

EI Salvador	OELVIE	Registered	20080104813	0011000111	No
EU	ADEPZAR	Registered	002519080	002519080	No
EU	BENLISTA	Registered	006857775	006857775	No
EU	BENLYSTA	Registered	005951141	005951141	No
EU	BENLYSTA and device	Registered	008869018	008869018	No
EU	BENLYSTA device	Registered	008868952	008868952	No
EU	BENLYSTIA	Registered	006857338	006857338	No
EU	LERSENA	Registered	934512	934512	Yes
EU	OELVIE	Registered	004121026	004121026	No
EU	THE US IN LUPUS	Registered	009951476	009951476	No
EU	THE US IN LUPUS device	Registered	009952185	009952185	No
EU	VARSIMLA	Registered	005951215	005951215	No
EU	VELARBA	Registered	005951223	005951223	No
Gambia	OELVIE	Application	12142008	11967	No
Gaza	OELVIE	Registered	12257	12257	No
Georgia	OELVIE	Registered	926205	926205	Yes
Ghana	OELVIE	Registered	33608	38221	No
Guatemala	BENLYSTA	Application	2011010304		No
Guatemala	OELVIE	Registered	7182008	157932	No
Guernsey	OELVIE	Registered	6083	GT6263	No
Guyana	OELVIE	Registered	22488	22488	No
Honduras	BENLYSTA	Registered	396252011	120232	No
Honduras	OELVIE	Registered	49662008	106012	No
Hong Kong	BENLISTA	Registered	301634995	301634995	No
Hong Kong	BENLYSTA	Registered	301634968	301634968	No

Hong Kong	BENLYSTA/BENLISTA in chinese (baan laup su)	Registered	301635020	301635020	301635020	No
Hong Kong	BENLYSTA IN CHINESE (series of 2)	Registered	302145906	302145906	302145906	No
Hong Kong	BENLYSTIA	Registered	301634940	301634940	301634940	No
Hong Kong	BENLYSTIA in chinese (baan lei siu)	Registered	301635011	301635011	301635011	No
Hong Kong	BENLYSTIA in chinese (baan siu daak)	Registered	301634986	301634986	301634986	No
Hong Kong	OELVIE	Registered	301046871	301046871	301046871	No
Hong Kong	OELVIE in traditional chinese (ho tak faai)	Registered	301261917	301261917	301261917	No
Hong Kong	OELVIE in traditional chinese (ou tak fei)	Registered	301261908	301261908	301261908	No
Iceland	OELVIE	Registered	926205	926205	926205	Yes
India	BENLISTA	Application	1810727	1810727		No
India	BENLYSTA	Application	1810725	1810725		No
India	BENLYSTIA	Application	1810726	1810726		No
India	LINBELIN	Registered	1742799	1742799	1742799	No
India	OELVIE	Registered	1658665	1658665	1658665	No
Indonesia	OELVIE	Registered	D002008004804	D002008004804	IDM000217501	No
Iran	OELVIE	Registered	926205	926205	926205	Yes
Iraq	OELVIE	Application	51882	51882		No
Israel	BENLYSTA	Application	238183	238183		No
Israel	OELVIE	Registered	207903	207903	207903	No
Jamaica	BENLYSTA	Registered	59443	59443	59443	No
Jamaica	OELVIE	Registered	51593	51593	51593	No
Japan	ADEPZAR	Registered	200114392	200114392	4912079	No

Japan	BENLISTA	Registered	200831424	5292385	No
Japan	BENLYSTA	Registered	200754560	5101055	No
Japan	BENLYSTA in katakana	Registered	200867496	5224300	No
Japan	BENLYSTIA	Registered	200831425	5236650	No
Japan	BENLYSTIA in katakana (be-n-ri-su-te-a)	Registered	200867498	5224302	No
Japan	BENLYSTIA in katakana (be-n-ri-su-thi-a)	Registered	200867497	5224301	No
Japan	OELVIE	Registered	2004106278	4849269	No
Japan	VARSIMLA	Registered	2007054560	5101055	No
Japan	VARSIMLA	Registered	2007054561	5101056	No
Japan	VELARBA	Registered	2007054562	5101057	No
Jersey	OELVIE	Registered	8840	8840	No
Jordan	BENLYSTA	Registered	121371	121371	No
Jordan	OELVIE	Registered	97430	97430	No
Kazakhstan	BENLYSTA	Application	55618		No
Kazakhstan	BENLYSTA in russian cyrillic	Application	56705		No
Kazakhstan	OELVIE	Registered	45734	32243	No
Kenya	OELVIE	Registered	926205	926205	Yes
Kuwait	BENLYSTA	Application	126673		No
Kuwait	OELVIE	Registered	92065	78177	No
Kyrgyz Republic	OELVIE	Registered	926205	926205	Yes
Lebanon	BENLYSTA	Registered	139775	139775	No
Lebanon	OELVIE	Registered	1069	115060	No

Liberia	OELVIE	Registered	LRM200800029	LRM200800029	No
Liechtenstein	OELVIE	Registered	926205	926205	Yes
Macao	BENLYSTA	Registered	59172	N059172	No
Macao	BENLYSTA IN CHINESE (series of 2)	Application	N62825		No
Macedonia	OELVIE	Registered	926205	926205	Yes
Madagascar	OELVIE	Registered	20080206	09667	No
Malawi	OELVIE	Registered	MWTM200800128	MWTM200800128	No
Malaysia	BENLYSTA	Application	2011010398		No
Malaysia	OELVIE	Registered	200803222	200803222	No
Mauritius	OELVIE	Application	07020		No
Mexico	ADEPZAR	Registered	1247684	1295506	No
Mexico	BENLISTA	Registered	929206	1048566	No
Mexico	BENLYSTA	Registered	858204	1004885	No
Mexico	BENLYSTA IV	Registered	1134199	1203053	No
Mexico	BENLYSTIA	Registered	929204	1048564	No
Mexico	BENLYSTIA IV	Application			No
Mexico	LERSENA	Registered	878629	1004696	No
Mexico	LINBELAR	Registered	929205	1048565	No
Mexico	LINBELIN	Registered	929203	1048563	No
Mexico	OELVIE	Registered	860448	996463	No
Mexico	VARSIMLA	Registered	858197	1022284	No
Mexico	VELARBA	Registered	858199	1022285	No
Moldova	OELVIE	Registered	926205	926205	Yes
Monaco	OELVIE	Registered	926205	926205	Yes
Mongolia	OELVIE	Registered	926205	926205	Yes

Montenegro (Republic of)	OELVIE	Registered	926205	926205	926205	Yes
Morocco	OELVIE	Registered	926205	926205	926205	Yes
Mozambique	OELVIE	Registered	926205	926205	926205	Yes
Namibia	OELVIE	Application	20081448			No
New Zealand	OELVIE	Registered	783377	783377	783377	No
Nicaragua	BENLYSTA	Application	2011004554			No
Nicaragua	OELVIE	Registered	200800703	200800703	0900712LM	No
Nigeria	OELVIE	Registered	FTM20086577	FTM20086577	RTM82739	No
North Korea (Peoples Democratic Republic of)	OELVIE	Registered	926205	926205	926205	Yes
Norway	ADEPZAR	Registered	200200036	200200036	214900	No
Norway	BENLYSTA	Registered	200811093	200811093	248989	No
Norway	BENLYSTA	Registered	200706255	200706255	243232	No
Norway	BENLYSTA	Registered	200811099	200811099	248990	No
Norway	LINBELIN	Registered	200814922	200814922	249906	No
Norway	OELVIE	Registered	200801285	200801285	246218	No
Norway	OELVIE	Registered	926205	926205	926205	Yes
Norway	VARSIMLA	Registered	200706257	200706257	243234	No
Norway	VELARBA	Registered	200706256	200706256	243233	No
OAPI (African Union)	OELVIE	Registered	3200800404	3200800404	58311	No
Oman	BENLYSTA	Application	72194	72194		No
Oman	OELVIE	Registered	926205	926205	926205	Yes
Pakistan	BENLYSTA	Application	307920	307920		No
Pakistan	OELVIE	Registered	246313	246313	246313	No

Panama	OELVIE	Registered	16829201	16829201	No
Paraguay	OELVIE	Registered	342652008	329209	No
Peru	BENLYSTA	Registered	466072	00183952	No
Peru	OELVIE	Registered	341918	00138797	No
Philippines	BENLYSTA	Registered	42011006437	42011006437	No
Philippines	OELVIE	Registered	042008001572	42008001572	No
Philippines	OELVIE	Registered	42011501128	42011501128	No
Puerto Rico	OELVIE	Registered	75621	75621	No
Qatar	BENLYSTA	Application	71660		No
Qatar	OELVIE	Registered	49036	49036	No
Russian Federation	BENLISTA	Registered	2008728922	395895	No
Russian Federation	BENLYSTA	Registered	2008728923	395896	No
Russian Federation	BENLYSTA/BENLISTA in russian cyrillic	Registered	2010716166	432068	No
Russian Federation	BENLYSTA	Registered	2008728919	395893	No
Russian Federation	LINBELIN	Registered	2008728921	395894	No
Russian Federation	OELVIE	Registered	926205	926205	Yes
Rwanda	OELVIE	Registered	6197	6197	No
San Marino	OELVIE	Registered	926205	926205	Yes
Saudi Arabia	BENLYSTA	Application	172840		No
Saudi Arabia	OELVIE	Registered	126944		No
Serbia (Republic of)	BENLYSTA	Registered	201126111	63990	No
Serbia (Republic of)	OELVIE	Registered	926205	926205	Yes


Sierra Leone	O DELVIE	Application	18733			No
Singapore	BENLISTA	Registered	T0811890J	T0811890J		No
Singapore	BENLYSTA	Registered	T0811897H	T0811897H		No
Singapore	BENLYSTIA	Registered	T0811889G	T0811889G		No
Singapore	LINBELIN	Registered	T0811887J	T0811887J		No
Singapore	O DELVIE	Registered	926205	926205		Yes
Sint Maarten (NL part of Saint Martin)	O DELVIE	Registered	926205	926205		Yes
South Africa	O DELVIE	Registered	200801729	200801729		No
South Korea (Republic of)	BENLISTA	Registered	200843657	802925		No
South Korea (Republic of)	BENLYSTA	Registered	200843655	802923		No
South Korea (Republic of)	BENLYSTA/BENLISTA in korean	Registered	201023649	4086837		No
South Korea (Republic of)	BENLYSTIA	Registered	200843656	802924		No
South Korea (Republic of)	BENLYSTIA in korean	Registered	201023650	40863436		No
South Korea (Republic of)	LINBELIN	Registered	200843658	802926		No
South Korea (Republic of)	O DELVIE	Registered	926205	926205		Yes
Sri Lanka	O DELVIE	Application	144102			No
Sudan	O DELVIE	Application	38579			No
Swaziland	O DELVIE	Application	35308			No
Switzerland	ADEPZAR	Registered	121832001	497099		No
Switzerland	BENLISTA	Registered	552042008	575810		No
Switzerland	BENLYSTA	Registered	557212007	561851		No

Switzerland	BENLYSTIA	Registered	552062008	575811	No
Switzerland	LERSENA	Registered	934512	934512	Yes
Switzerland	LINBELAR	Registered	552152008	575813	No
Switzerland	LINBELIN	Registered	552102008	575812	No
Switzerland	OELVIE	Registered	580582004	529951	No
Switzerland	VARSIMLA	Registered	557222007	561852	No
Switzerland	VELARBA	Registered	557242007	561853	No
Syria	BENLYSTA	Application	1097721	1097721	Yes
Syria	OELVIE	Registered	926205	926205	Yes
Taiwan	BENLYSTA	Registered	099007301	1426687	No
Taiwan	BENLYSTA in traditional chinese (ben-li-sheng)	Registered	099007300	1426686	No
Taiwan	OELVIE	Registered	097005956	1332533	No
Tajikistan	OELVIE	Registered	08008766	8562	No
Tanganyika (Tanzania Republic)	OELVIE	Application	TZT20081143		No
Thailand	BENLYSTA	Application	809843		No
Thailand	BENLYSTA in thai	Application	827832		No
Thailand	OELVIE	Registered	686162	KOR307197	No
Trinidad and Tobago	BENLYSTA	Application	44614		No
Trinidad and Tobago	OELVIE	Registered	39445	39445	No
Tunisia	OELVIE	Registered	EE080605	EE080605	No
Turkey	BENLISTA	Registered	200871384	200871384	No
Turkey	BENLYSTA	Registered	200871383	200871383	No

Turkey	BENLYSTIA	Registered	200871385	200871385	No
Turkey	LINBELIN	Registered	200871386	200871386	No
Turkey	OELVIE	Registered	926205	926205	Yes
Turkmenistan	OELVIE	Registered	926205	926205	Yes
Uganda	OELVIE	Registered	30689	30689	No
UK	LERSENA	Registered	2454618	2454618	No
UK	OELVIE	Registered	2364142	2364142	No
Ukraine	BENLYSTA	Application	M201104353		No
Ukraine	BENLYSTA/BENLISTA in ukrainian cyrillic	Application	M201104355		No
Ukraine	OELVIE	Registered	926205	926205	Yes
United Arab Emirates	BENLYSTA	Application	165979		No
United Arab Emirates	OELVIE	Registered	106554	99519	No
Uruguay	BENLYSTA	Application	430587		No
Uruguay	OELVIE	Registered	388248	388248	No
USA	BENLYSTA	Application	85235903		No
USA	BENLYSTA	Registered	77979299	3797552	No
USA	BENLYSTA device	Application	77924724		No
USA	BENLYSTA device	Registered	77981922	4057042	No
USA	LIMILYS	Application	85257452		No
USA	LINBELA	Application	85257469		No
USA	LYMPHOSTAT-B	Registered	76283659	2908983	No
USA	OELVIE	Registered	78437623	3329040	No
USA	THE US IN LUPUS	Application	85173309		No
USA	THE US IN LUPUS	Registered	85976164	4116311	No

USA	THE US IN LUPUS device	Application	85173288		No
USA	VARSIMLA	Application	85257457		No
USA	VELARBA	Application	85257471		No
USA	WELZERA	Application	85257463		No
Uzbekistan	OELVIE	Registered	926205	926205	Yes
Venezuela	BENLISTA	Registered	2008018374	P306351	No
Venezuela	BENLYSTA	Registered	2008018371	P306781	No
Venezuela	BENLYSTIA	Registered	2008018373	P306782	No
Venezuela	LINBELIN	Application	2008018372		No
Venezuela	OELVIE	Registered	180008	P289750	No
Vietnam	OELVIE	Registered	926205	926205	Yes
West Bank	OELVIE	Registered	14586	14586	No
WIPO	BENLYSTA	Application	1097721	1097721	Yes
WIPO	LERSENA	Registered	934512	934512	Yes
WIPO	OELVIE	Registered	926205	926205	Yes
Yemen (Republic of)	OELVIE	Registered	42453	34547	No
Zambia	OELVIE	Registered	1702008	1702008	No
Zanzibar (Tanzania Republic)	OELVIE	Registered	752008	0752008	No
Zimbabwe	OELVIE	Registered	972008	972008	No

Signed by)
)
CHESTER KOCZYNSKI)
For and on behalf of HUMAN)
GENOME SCIENCES INC)
)


PRESIDENT

Signed by)
)
)
)
For and on behalf of)
GLAXOSMITHKLINE)
INTELLECTUAL PROPERTY)
LIMITED)

514204275

Signed by)
)
)
)
)
 For and on behalf of HUMAN)
 GENOME SCIENCES INC)
)

Signed by)
)
)
)
)
 For and on behalf of)
 GLAXOSMITHKLINE)
 INTELLECTUAL PROPERTY)
 LIMITED)



Paul Williamson
 Authorised Signatory
 For and on behalf of
 Glaxo Group Limited
 Corporate Director

514204275